{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:59:59Z","timestamp":1792699199075,"version":"4.5.0"},"reference-count":94,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>Although designer benzodiazepines (DBZDs) constitute a minor part of new psychoactive substances, they deserve the greatest attention because of their popularity among drug users and increasing number and availability. This review covers the effects of different DBZDs, available pharmacological evaluation tools, and their reported toxicity and potential pharmacodynamic and pharmacokinetic interactions with other drugs commonly co-abused with DBZDs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>For this narrative review, a nonsystematic search was performed on PubMed, EMBASE, Google Scholar, and PubMed Central databases between June and July 2021.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The current consensus hypothesis suggests that DBZDs mediate their effects through interactions with the GABA<jats:sub>A<\/jats:sub> receptor, producing similar effects to benzodiazepines used in therapy, including sedation, hypnosis, anxiolysis, muscle relaxation, euphoria, amnesia, and addiction. Owing to the complexity of their action mechanism and the numerous GABA<jats:sub>A<\/jats:sub> subtype receptors, the pharmacodynamic metrics of DBZDs are very difficult to establish. The pharmacological effects of DBZD are related to their structure, influencing their binding to GABA<jats:sub>A<\/jats:sub> receptor subunits. Quantitative structure\u2013activity relationship studies successfully predicted the biological activity and relative potency of DBZD but could not predict the main pharmacological effect of a given DBZD. Exploring the effects by netnographic studies is one of the available alternatives, despite its limitations. DBZDs are usually identified in the context of polysubstance use. Pharmacodynamic interactions between DBZDS and other CNS depressants, such as opioids, have been extensively reported. However, pharmacokinetic interactions between DBZDs and opioids are considered less important, and contradictory conclusions about their clinical significance have been reported.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Understanding the mechanism of action and other pharmacological metrics is highly important in the clinical management of DBZDs.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001071","type":"journal-article","created":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T04:00:36Z","timestamp":1675828836000},"page":"494-507","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Designer Benzodiazepines: Effects, Toxicity, and Interactions"],"prefix":"10.1097","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9743-5603","authenticated-orcid":false,"given":"Souleiman","family":"El Balkhi","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Toxicology and Pharmacovigilance, Limoges University Hospital, Limoges ;"},{"name":"INSERM, UMR 1248, 87000, Limoges ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chadi","family":"Abbara","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Toxicology and Pharmacovigilance, Angers University Hospital, Angers, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,1,27]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"11976J","DOI":"10.1520\/JFS11976J","article-title":"Designer drugs: past history and future prospects","volume":"33","author":"Henderson","year":"1988","journal-title":"J Forensic Sci."},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1017\/S0033291719001727","article-title":"New\/emerging psychoactive substances and associated psychopathological consequences","volume":"51","author":"Schifano","year":"2019","journal-title":"Psychol Med."},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/02791072.2014.944291","article-title":"Spice,\u201d \u201cKryptonite,\u201d \u201cBlack Mamba\u201d: an overview of brand names and marketing strategies of novel psychoactive substances on the web","volume":"46","author":"Corazza","year":"2014","journal-title":"J Psychoactive Drugs"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2174\/1570159X18666200110121333","article-title":"\u2018New\/Designer benzodiazepines\u2019: an analysis of the literature and psychonauts' trip reports","volume":"18","author":"Orsolini","year":"2020","journal-title":"Curr Neuropharmacology"},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/15563650.2018.1506130","article-title":"Occurrence and time course of NPS benzodiazepines in Sweden \u2013 results from intoxication cases in the STRIDA project","volume":"57","author":"B\u00e4ckberg","year":"2018","journal-title":"Clin Toxicol."},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s00204-020-02693-7","article-title":"Designer drugs: mechanism of action and adverse effects","volume":"94","author":"Luethi","year":"2020","journal-title":"Arch Toxicol."},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.drugalcdep.2012.07.004","article-title":"Polydrug abuse: a review of opioid and benzodiazepine combination use","volume":"125","author":"Jones","year":"2012","journal-title":"Drug Alcohol Dependence"},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.neuro.2019.02.015","article-title":"An expanding world of new psychoactive substances\u2014designer benzodiazepines","volume":"73","author":"Zawilska","year":"2019","journal-title":"NeuroToxicology"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/164_2018_154","article-title":"Designer benzodiazepines: another class of new psychoactive substances","volume":"252","author":"Moosmann","year":"2018","journal-title":"Handb Exp Pharmacol."},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/164_2018_154","article-title":"Designer benzodiazepines: another class of new psychoactive substances","volume":"252","author":"Moosmann","year":"2018","journal-title":"Handbook Exp Pharmacol."},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/jms.3279","article-title":"Detection and identification of the designer benzodiazepine flubromazepam and preliminary data on its metabolism and pharmacokinetics","volume":"48","author":"Moosmann","year":"2013","journal-title":"J Mass Spectrom."},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s11419-013-0187-4","article-title":"Characterization of the designer benzodiazepine pyrazolam and its detectability in human serum and urine","volume":"31","author":"Moosmann","year":"2013","journal-title":"Forensic Toxicol."},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11419-016-0338-5","article-title":"Metabolites replace the parent drug in the drug arena. The cases of fonazepam and nifoxipam","volume":"35","author":"Katselou","year":"2016","journal-title":"Forensic Toxicol."},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1208\/s12248-016-0040-x","article-title":"Identifying metabolites of meclonazepam by high-resolution mass spectrometry using human liver microsomes, hepatocytes, a mouse model, and authentic urine samples","volume":"19","author":"Vikingsson","year":"2017","journal-title":"AAPS J."},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000137913","article-title":"Pharmacokinetics of benzodiazepine hypnotics","volume":"27","author":"Greenblatt","year":"1983","journal-title":"Pharmacology"},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/BF03189565","article-title":"Species differences in phenazeram kinetics and metabolism","volume":"7","author":"Zherdev","year":"1982","journal-title":"Eur J Drug Metab Pharmacokinet."},{"key":"R32-20250603","doi-asserted-by":"crossref","first-page":"700","DOI":"10.3389\/fpsyt.2020.00700","article-title":"New trends of substance abuse during COVID-19 pandemic: an international perspective","volume":"11","author":"Zaami","year":"2020","journal-title":"Front Psychiatry"},{"key":"R33-20250603","doi-asserted-by":"crossref","first-page":"110595","DOI":"10.1016\/j.forsciint.2020.110595","article-title":"A comprehensive analytical process, from NPS threat identification to systematic screening: method validation and one-year prevalence study","volume":"318","author":"Garneau","year":"2021","journal-title":"Forensic Sci Int."},{"key":"R34-20250603","doi-asserted-by":"crossref","first-page":"109244","DOI":"10.1016\/j.drugalcdep.2021.109244","article-title":"Significant Toxicity Following an Increase in Poisonings with Designer Benzodiazepines in the Netherlands between 2010 and 2020","volume":"231","author":"Essink","year":"2022","journal-title":"Drug Alcohol Dependence"},{"key":"R35-20250603","doi-asserted-by":"crossref","first-page":"162","DOI":"10.15288\/jsad.2022.83.162","article-title":"Designer benzodiazepines and sleep disorders: a rise of two interacting problems?","volume":"83","author":"Dokkedal-Silv","year":"2022","journal-title":"J Stud Alcohol Drugs"},{"key":"R37-20250603","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1176\/appi.ps.201800321","article-title":"Benzodiazepine use and misuse among adults in the United States","volume":"70","author":"Maust","year":"2019","journal-title":"Psychiatr Serv."},{"key":"R38-20250603","doi-asserted-by":"crossref","first-page":"686","DOI":"10.2105\/AJPH.2016.303061","article-title":"Increasing benzodiazepine prescriptions and overdose mortality in the United States, 1996\u20132013","volume":"106","author":"Bachhuber","year":"2016","journal-title":"Am J Public Health"},{"key":"R40-20250603","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1016\/j.addbeh.2013.05.008","article-title":"Treatment or \"high\": benzodiazepine use in patients on injectable heroin or oral opioids","volume":"38","author":"Vogel","year":"2013","journal-title":"Addict Behaviors"},{"key":"R43-20250603","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s11062-014-9429-2","article-title":"Pharmacodynamical and neuroreceptor analysis of the permeability of the blood-brain barrier for derivatives of 1, 4-benzodiazepine","volume":"46","author":"Golovenko","year":"2014","journal-title":"Neurophysiology"},{"key":"R44-20250603","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/jhet.5570080222","article-title":"Quinazolines and 1, 4-benzodiazepines. LI. The synthesis of thet-butyl analog of diazepam","volume":"8","author":"Oilman","year":"1971","journal-title":"J Heterocyclic Chem."},{"key":"R46-20250603","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/dta.2349","article-title":"The emergence of new psychoactive substance (NPS) benzodiazepines: a review","volume":"10","author":"Manchester","year":"2018","journal-title":"Drug Test Anal."},{"key":"R47-20250603","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s00414-017-1541-6","article-title":"Characterization and identification of eight designer benzodiazepine metabolites by incubation with human liver microsomes and analysis by a triple quadrupole mass spectrometer","volume":"131","author":"El Balkhi","year":"2017","journal-title":"Int J Leg Med"},{"key":"R50-20250603","doi-asserted-by":"crossref","first-page":"008","DOI":"10.17352\/pjmcr.000002","article-title":"Recent structure activity relationship studies of 1, 4-benzodiazepines","author":"Qadir","year":"2015","journal-title":"Open J Chem."},{"key":"R51-20250603","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0031-6997(24)01363-2","article-title":"International Union of Pharmacology. XV. Subtypes of gamma-aminobutyric acidA receptors: classification on the basis of subunit structure and receptor function","volume":"50","author":"Barnard","year":"1998","journal-title":"Pharmacol Rev."},{"key":"R52-20250603","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0031-6997(25)06840-1","article-title":"Structure and pharmacology of gamma-aminobutyric acidA receptor subtypes","volume":"47","author":"Sieghart","year":"1995","journal-title":"Pharmacol Rev."},{"key":"R53-20250603","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.tips.2018.03.006","article-title":"The benzodiazepine binding sites of GABAA receptors","volume":"39","author":"Sigel","year":"2018","journal-title":"Trends Pharmacol Sci"},{"key":"R55-20250603","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nchembio.917","article-title":"Diazepam-bound GABAA receptor models identify new benzodiazepine binding-site ligands","volume":"8","author":"Richter","year":"2012","journal-title":"Nat Chem Biol."},{"key":"R56-20250603","doi-asserted-by":"crossref","first-page":"833","DOI":"10.2174\/1568026023393444","article-title":"Mapping of the benzodiazepine recognition site on GABA-A receptors","volume":"2","author":"Sigel","year":"2002","journal-title":"Curr Top Med Chem."},{"key":"R57-20250603","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1124\/mol.118.114975","article-title":"Identifying drugs that bind selectively to intersubunit general anesthetic sites in the \u03b11\u03b23\u03b32 GABAAR transmembrane domain","volume":"95","author":"Jayakar","year":"2019","journal-title":"Mol Pharmacol."},{"key":"R59-20250603","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1021\/cn5000056","article-title":"Classics in chemical neuroscience: diazepam (valium)","volume":"5","author":"Calcaterra","year":"2014","journal-title":"ACS Chem Neurosci."},{"key":"R60-20250603","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/ijms23010042","article-title":"High-dose benzodiazepines positively modulate GABAA receptors via a flumazenil-insensitive mechanism","volume":"23","author":"Wang","year":"2021","journal-title":"Int J Mol Sci."},{"key":"R61-20250603","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.3390\/ijms20133348","article-title":"VDAC1 and the TSPO: expression, interactions, and associated functions in health and Disease states","volume":"20","author":"Shoshan-Barmatz","year":"2019","journal-title":"Int J Mol Sci."},{"key":"R63-20250603","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1021\/acsomega.9b04000","article-title":"Ortho versus meta chlorophenyl-2, 3-benzodiazepine analogues: synthesis, molecular modeling, and biological activity as AMPAR antagonists","volume":"5","author":"Qneibi","year":"2020","journal-title":"ACS Omega"},{"key":"R64-20250603","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.scijus.2017.12.004","article-title":"The use of a quantitative structure-activity relationship (QSAR) model to predict GABA-A receptor binding of newly emerging benzodiazepines","volume":"58","author":"Waters","year":"2018","journal-title":"Sci Justice"},{"key":"R65-20250603","first-page":"165","article-title":"Recent advances in the molecular pharmacology of benzodiazepine receptors and in the structure-activity relationships of their agonists and antagonists","volume":"14","author":"Haefely","year":"1985","journal-title":"Adv Drug Res."},{"key":"R66-20250603","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.tips.2014.12.001","article-title":"Beware of docking","volume":"36","author":"Chen","year":"2015","journal-title":"Trends Pharmacol Sci."},{"key":"R67-20250603","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1021\/jm00004a017","article-title":"Prediction of receptor properties and binding affinity of ligands to benzodiazepine\/GABAA receptors using artificial neural networks","volume":"38","author":"Maddalena","year":"2002","journal-title":"J Med Chem."},{"key":"R68-20250603","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1021\/ci990307l","article-title":"Prediction of physicochemical parameters by atomic contributions","volume":"39","author":"Wildman","year":"1999","journal-title":"J Chem Inf Comput Sci."},{"key":"R70-20250603","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/1556-4029.14893","article-title":"Flualprazolam distribution in postmortem samples","volume":"67","author":"Ha","year":"2022","journal-title":"J Forensic Sci."},{"key":"R71-20250603","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/jat\/bkaa098","article-title":"Quantification of flualprazolam in blood by LC-MS-MS: a case series of nine deaths","volume":"45","author":"Rice","year":"2021","journal-title":"J Anal Toxicol."},{"key":"R72-20250603","first-page":"bkac017","article-title":"The evolution towards designer benzodiazepines in drug-facilitated sexual assault cases.","author":"P\u00e9rez Orts","year":"2022","journal-title":"J Anal Toxicol."},{"key":"R73-20250603","doi-asserted-by":"crossref","first-page":"111324","DOI":"10.1016\/j.forsciint.2022.111324","article-title":"Toxicity of designer benzodiazepines: a case of etizolam and cocaine intoxication","volume":"336","author":"Drevin","year":"2022","journal-title":"Forensic Sci Int."},{"key":"R74-20250603","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1093\/jat\/bkaa146","article-title":"A case series of etizolam in opioid-related deaths","volume":"45","author":"Gevorkyan","year":"2021","journal-title":"J Anal Toxicol."},{"key":"R75-20250603","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.tins.2011.01.004","article-title":"Hooked on benzodiazepines: GABAA receptor subtypes and addiction","volume":"34","author":"Tan","year":"2011","journal-title":"Trends Neurosciences"},{"key":"R77-20250603","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41586-018-0255-3","article-title":"Structure of a human synaptic GABAA receptor","volume":"559","author":"Zhu","year":"2018","journal-title":"Nature"},{"key":"R78-20250603","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.neuropharm.2018.01.036","article-title":"GABAA receptor: positive and negative allosteric modulators","volume":"136","author":"Olsen","year":"2018","journal-title":"Neuropharmacology"},{"key":"R79-20250603","doi-asserted-by":"crossref","first-page":"28674","DOI":"10.1038\/srep28674","article-title":"Zolpidem is a potent stoichiometry-selective modulator of \u03b11\u03b23 GABAA receptors: evidence of a novel benzodiazepine site in the \u03b11-\u03b11 interface","volume":"6","author":"Che Has","year":"2016","journal-title":"Scientific Rep."},{"key":"R80-20250603","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41586-018-0832-5","article-title":"GABAA receptor signalling mechanisms revealed by structural pharmacology","volume":"565","author":"Masiulis","year":"2019","journal-title":"Nature"},{"key":"R81-20250603","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41586-020-2654-5","article-title":"Shared structural mechanisms of general anaesthetics and benzodiazepines","volume":"585","author":"Kim","year":"2020","journal-title":"Nature"},{"key":"R82-20250603","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.tips.2018.04.003","article-title":"An emerging circuit pharmacology of GABAA receptors","volume":"39","author":"Engin","year":"2018","journal-title":"Trends Pharmacol Sci."},{"key":"R83-20250603","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nrd3502","article-title":"Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes","volume":"10","author":"Rudolph","year":"2011","journal-title":"Nat Rev Drug Discov."},{"key":"R84-20250603","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/75761","article-title":"Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABAA receptor \u03b11 subtype","volume":"3","author":"McKernan","year":"2000","journal-title":"Nat Neurosci."},{"key":"R85-20250603","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1073\/pnas.0405621102","article-title":"Different GABAA receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates","volume":"102","author":"Rowlett","year":"2005","journal-title":"Proc Natl Acad Sci."},{"key":"R86-20250603","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1126\/science.290.5489.131","article-title":"Molecular and neuronal substrate for the selective attenuation of anxiety","volume":"290","author":"Lo\u0308w","year":"2000","journal-title":"Science"},{"key":"R87-20250603","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.2174\/156802611795371350","article-title":"GABAA receptor subtype-selective modulators. I. \u03b12\/\u03b13-Selective agonists as non-sedating anxiolytics","volume":"11","author":"R Atack","year":"2011","journal-title":"Curr Top Med Chem."},{"key":"R88-20250603","doi-asserted-by":"crossref","first-page":"10682","DOI":"10.1523\/JNEUROSCI.1166-05.2005","article-title":"Evidence for a significant role of 3-containing GABAA receptors in mediating the anxiolytic effects of benzodiazepines","volume":"25","author":"Dias","year":"2005","journal-title":"J Neurosci."},{"key":"R89-20250603","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1038\/npp.2016.49","article-title":"A pharmacogenetic \u2018restriction-of-function\u2019 approach reveals evidence for anxiolytic-like actions mediated by \u03b15-containing GABAA receptors in mice","volume":"41","author":"Behlke","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"R90-20250603","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1038\/nn.4102","article-title":"Regulating anxiety with extrasynaptic inhibition","volume":"18","author":"Botta","year":"2015","journal-title":"Nat Neurosci."},{"key":"R91-20250603","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.neuropharm.2008.07.045","article-title":"GABA A receptors: subtypes provide diversity of function and pharmacology","volume":"56","author":"Olsen","year":"2009","journal-title":"Neuropharmacology"},{"key":"R92-20250603","doi-asserted-by":"crossref","first-page":"40224","DOI":"10.1074\/jbc.R112.386664","article-title":"Structure, function, and modulation of GABAA receptors","volume":"287","author":"Sigel","year":"2012","journal-title":"J Biol Chem."},{"key":"R93-20250603","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.tins.2020.10.011","article-title":"Regulation of GABAARs by transmembrane accessory proteins","volume":"44","author":"Han","year":"2021","journal-title":"Trends Neurosciences"},{"key":"R94-20250603","doi-asserted-by":"crossref","first-page":"616298","DOI":"10.3389\/fnins.2020.616298","article-title":"Looking for novelty in an \u201cold\u201d receptor: recent advances toward our understanding of GABAARs and their implications in receptor pharmacology","volume":"14","author":"Castellano","year":"2020","journal-title":"Front Neurosci."},{"key":"R95-20250603","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.forsciint.2010.06.030","article-title":"\u201cLegal highs\u201d on the net-Evaluation of UK-based Websites, products and product information","volume":"206","author":"Schmidt","year":"2011","journal-title":"Forensic Sci Int."},{"key":"R96-20250603","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/hup.2299","article-title":"Promoting innovation and excellence to face the rapid diffusion of novel psychoactive substances in the EU: the outcomes of the ReDNet project","volume":"28","author":"Corazza","year":"2013","journal-title":"Hum Psychopharmacol Clin Exp."},{"key":"R97-20250603","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.drugpo.2017.11.003","article-title":"The diverse reasons for using Novel Psychoactive Substances - a qualitative study of the users' own perspectives","volume":"52","author":"Soussan","year":"2018","journal-title":"Int J Drug Pol."},{"key":"R98-20250603","first-page":"SART.S22495","article-title":"Chasing the high\" - experiences of ethylphenidate as described on international internet forums","volume":"9","author":"Soussan","year":"2015","journal-title":"Substance Abuse: Res Treat."},{"key":"R99-20250603","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1477-7517-11-25","article-title":"Harm reduction and knowledge exchange-a qualitative analysis of drug-related Internet discussion forums","volume":"11","author":"Soussan","year":"2014","journal-title":"Harm Reduction J."},{"key":"R100-20250603","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1089\/cyber.2014.0486","article-title":"Mind navigators of chemicals' experimenters? A web-based description of e-psychonauts","volume":"18","author":"Orsolini","year":"2015","journal-title":"Cyberpsychology, Behav Soc Networking"},{"key":"R101-20250603","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3109\/09638237.2012.682265","article-title":"e-Psychonauts: conducting research in online drug forum communities","volume":"21","author":"Davey","year":"2012","journal-title":"J Ment Health"},{"key":"R102-20250603","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1080\/02791072.2013.803647","article-title":"Methoxetamine (MXE) - a phenomenological study of experiences induced by a \u201clegal high\u201d from the internet","volume":"45","author":"Kjellgren","year":"2013","journal-title":"J Psychoactive Drugs"},{"key":"R103-20250603","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/02791072.2014.934979","article-title":"An internet study of user's experiences of the synthetic cathinone 4-methylethcathinone (4-MEC)","volume":"46","author":"Van Hout","year":"2014","journal-title":"J Psychoactive Drugs"},{"key":"R104-20250603","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.forsciint.2016.08.013","article-title":"An overview of emerging and new psychoactive substances in the United Kingdom","volume":"267","author":"Beharry","year":"2016","journal-title":"Forensic Sci Int."},{"issue":"7","key":"R105-20250603","doi-asserted-by":"crossref","first-page":"e24433","DOI":"10.2196\/24433","article-title":"Self-reported subjective effects of analytically confirmed new psychoactive substances consumed by e-psychonauts: a protocol for a longitudinal study using a new, internet-based methodology (Preprint)","volume":"10","author":"Grifell","year":"2020","journal-title":"JMIR Res Protoc."},{"key":"R106-20250603","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1177\/0269881119901096","article-title":"Designer benzodiazepines' pharmacological effects and potencies: how to find the information","volume":"34","author":"El Balkhi","year":"2020","journal-title":"J Psychopharmacol."},{"key":"R107-20250603","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/qjmed\/hcq056","article-title":"Purchasing 'legal highs' on the Internet--is there consistency in what you get?","volume":"103","author":"Davies","year":"2010","journal-title":"QJM"},{"key":"R108-20250603","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1089\/cyber.2014.0486","article-title":"Mind navigators of chemicals' experimenters? A web-based description of E-psychonauts","volume":"18","author":"Orsolini","year":"2015","journal-title":"Cyberpsychology, Behav Soc Networking"},{"key":"R109-20250603","doi-asserted-by":"crossref","first-page":"e2573","DOI":"10.1002\/hup.2573","article-title":"An insight into the deep web; why it matters for addiction psychiatry?","volume":"32","author":"Orsolini","year":"2017","journal-title":"Hum Psychopharmacol Clin Exp."},{"key":"R110-20250603","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1080\/15563650.2018.1510502","article-title":"Designer benzodiazepines: a report of exposures recorded in the national poison data system, 2014-2017","volume":"57","author":"Carpenter","year":"2019","journal-title":"Clin Toxicol."},{"key":"R111-20250603","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/1455072517706304","article-title":"The slippery slope of flubromazolam: experiences of a novel psychoactive benzodiazepine as discussed on a Swedish online forum","volume":"34","author":"Andersson","year":"2017","journal-title":"Nordic Stud Alcohol Drugs"},{"key":"R112-20250603","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1023\/A:1005520523502","article-title":"Chronic liver injury related to use of bentazepam: an unusual instance of benzodiazepine hepatotoxicity","volume":"45","author":"Andrade","year":"2000","journal-title":"Dig Dis Sci."},{"key":"R113-20250603","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ajp.2018.07.019","article-title":"Etizolam withdrawal catatonia: the first case report","volume":"37","author":"Banerjee","year":"2018","journal-title":"Asian J Psychiatry"},{"key":"R114-20250603","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/ADM.0000000000000884","article-title":"Evidence of designer benzodiazepine use in routine healthcare urine drug specimens","volume":"16","author":"Garland","year":"2022","journal-title":"J Addict Med."},{"key":"R115-20250603","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s13181-018-0659-3","article-title":"Assessment of the availability, cost, and motivations for use over time of the new psychoactive substances\u2014benzodiazepines diclazepam, flubromazepam, and pyrazolam\u2014in the UK","volume":"14","author":"Abouchedid","year":"2018","journal-title":"J Med Toxicol."},{"key":"R117-20250603","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/bcpt.12655","article-title":"The pharmacology and toxicology of the \u2018holy trinity","volume":"120","author":"Horsfall","year":"2017","journal-title":"Basic Clin Pharmacol Toxicol."},{"key":"R118-20250603","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/add.15095","article-title":"Benzodiazepines: the time for systematic change is now","volume":"116","author":"Schmitz","year":"2020","journal-title":"Addiction"},{"key":"R120-20250603","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00228-004-0789-1","article-title":"Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism","volume":"60","author":"Araki","year":"2004","journal-title":"Eur J Clin Pharmacol."},{"key":"R121-20250603","first-page":"1","article-title":"Metabolic interactions of benzodiazepines with oxycodone ex vivo and toxicity depending on usage patterns in an animal model","author":"Lawson","year":"2021","journal-title":"Br J Pharmacol."},{"key":"R122-20250603","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/jat\/bkaa043","article-title":"Blood concentrations of designer benzodiazepines: relation to impairment and findings in forensic cases","volume":"44","author":"Heide","year":"2020","journal-title":"J Anal Toxicol."},{"key":"R123-20250603","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1093\/jat\/bkac023","article-title":"Reports of adverse events associated with use of novel psychoactive substances, 2017\u20132020: a review","volume":"46","author":"Mohr","year":"2022","journal-title":"J Anal Toxicol."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001071","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:14:06Z","timestamp":1748970846000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,27]]},"references-count":94,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001071","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,27]]}}}